SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two upcoming investor conferences:
Baird Global Healthcare Conference
Dates: Wednesday - Thursday, September 4-5, 2019
Presentation: 10:15am ET, Thursday, September 5, 2019
Location: InterContinental New York Barclay, New York
Janney Montgomery Scott Healthcare Conference
Dates: Monday – Tuesday, September 9-10, 2019
Presentation: 9:55am ET, Tuesday, September 10, 2019
Location: The Union League Club, New York
The Company will also conduct one-on-one meetings. A copy of the TLC presentation can be accessed under “Events and Presentations” in the Investors section of TLC’s website at www.tlcbio.com.
About TLC
TLC (Nasdaq: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™). TLC believes that its deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.